Biotech, cancer, Inflammation Luke Timmerman wrote: Some members of the band that pumped out a one-hit wonder at Icos are getting back together to see if they can produce at least one more hit at Seattle-based Calistoga Pharmaceuticals. Calistoga has been building up its management team over the pas...

What are we to make of Roche's new $93 per share offer for Genentech? BNET previously suggested that market conditions were so rough that Genentech holders should take the low-ball $86.50 offer that Roche made when it went hostile a few weeks ago. Looks like that was wrong! Roche chairman Franz Hume...

Biotech, cancer, Drugs Luke Timmerman wrote: Nowhere but America makes it possible for a company to pursue its dreams for 28 years without making a profit. Even in the most optimistic times, it’s hard to explain. So how can it possibly be, in the depths of recession, that things are looking up...

Biotech, cancer, Drugs Luke Timmerman wrote: Off the coast of the Bahamas, in sea grass more than a half-mile deep, San Diego-based Nereus Pharmaceuticals found a fungus that may be the key ingredient for an innovative new cancer drug. This will be a key year for gathering evidence that will either ...

Biotech, VC, Life Sciences Luke Timmerman wrote: There are easier things to do these days than trying to organize a biotech investing conference in Seattle. The local cluster has taken its share of body blows, the weather is usually pretty gray in late winter, and investors aren’t in the mood ...

Biotech, acquisitions, Autoimmune Luke Timmerman wrote: Pfizer rocked the business world yesterday with its $68 billion bid to acquire Madison, NJ-based Wyeth (NYSE: WYE), and the ripple effect was felt here in the Northwest. Nobody in town has a bigger stake in this deal than Seattle-based Trubion ...

Biotech, Devices, people Luke Timmerman wrote: Washington state’s life sciences trade group has a new boss, Chris Rivera, who has made a career in the high-pressure world of sales and marketing of new biotech drugs. Rivera’s new challenge, starting this month, is to help strengthen this ...

Biotech, people, Life Sciences Luke Timmerman wrote: Most biotech companies live and die based on how much cash they have in the bank to fuel drug development. So we’ve combed through the cash statements of more than 70 publicly traded life sciences companies in Xconomy’s home cities of ...

Biotech, Cash, Life Sciences Luke Timmerman wrote: Boston is the biggest center of life sciences in the Xconomy network, and by our analysis, the Bay State’s biotech sector is also the best equipped to survive the economic crisis. I reached this conclusion by combing through public company fil...

South of the City and hard by the shores of San Francisco Bay, Genentech rarely attracts the attention of the founders of flashy Internet startups as they drive past its offices on the way to the airport. But the biotech company's longtime CEO, Art Levinson, is an integral part of the Silicon Valley...